# Mantle Cell Lymphoma

Confirm mantle cell lymphoma with tissue-based cyclin D1/CCND1 testing, distinguish its key diagnostic mimics, stage before treatment, and select induction intensity by fitness. Relapse management depends critically on prior BTK inhibitor exposure and eligibility for cellular therapy.

**Clinical question:** How should physicians confirm, risk-stratify, and sequence treatment for newly diagnosed or relapsed mantle cell lymphoma?

Updated: 2026-08-21T02:16:05.430197+00:00

## What matters in practice
- Do not diagnose MCL from a CD5-positive B-cell flow cytometry phenotype alone; confirm with cyclin D1 and/or CCND1 rearrangement testing, with SOX11 particularly useful when cyclin D1 is negative. [15][16][17][18]
- CD23 and CD200 positivity favors SLL/CLL, whereas MCL is typically CD23-negative and FMC7-positive; focal cyclin D1 staining in CLL/SLL proliferation centers is not diagnostic of MCL. [17]
- For symptomatic advanced MCL, use rituximab-containing chemotherapy and match intensity to physiologic fitness; cytarabine-containing induction and high-dose consolidation are options for fit patients with chemosensitive disease. [22]
- After one prior line, BTK inhibition is an established relapse-directed option; pirtobrutinib has FDA approval in relapsed/refractory MCL after at least two prior lines including a covalent BTK inhibitor. [3][22]
- At relapse, obtain a current biopsy when feasible if morphology, growth kinetics, or treatment response raises concern for blastoid/pleomorphic transformation or an alternative lymphoma. [15][17]

## Confirm MCL before selecting treatment

Resolve diagnostic mimics on excisional or core tissue rather than flow cytometry alone.

For a mature CD5-positive B-cell neoplasm, obtain tissue morphology, B-cell immunophenotyping, cyclin D1 immunohistochemistry, and CCND1 rearrangement testing by FISH when needed. The defining lesion is t(11;14)(q13;q32), juxtaposing CCND1 with the immunoglobulin heavy-chain locus and producing cyclin D1 overexpression. [16][17][20][21]

Use SOX11 staining to support conventional MCL when cyclin D1 is negative or technically equivocal. SOX11 is positive in more than 90% of MCL, including cyclin D1-negative and blastoid cases; rare cyclin D1-negative tumors may instead show high cyclin D2 or cyclin D3 expression. [15][16][17]

Review morphology and genetics with a hematopathologist when a cyclin D1-positive large B-cell process is encountered. Most DLBCL lacks CCND1/IGH rearrangement, cyclin D1, and SOX11, but rare DLBCL can express cyclin D1 without t(11;14) or SOX11 and can be mistaken for blastoid MCL. [15]
- If CD23 and CD200 are positive, prioritize SLL/CLL in the differential; typical MCL is CD23-negative and FMC7-positive. [17]
- Do not call MCL from focal cyclin D1 positivity in CLL/SLL proliferation centers; uniform cyclin D1 and SOX11 expression in the B-cell population supports MCL. [17]
- If cyclin D1 is negative and FISH does not show t(11;14), evaluate SOX11 and consider CCND2/CCND3-rearranged MCL in the appropriate morphologic and immunophenotypic setting. [15][16][17]

*Tissue-based distinctions among common CD5-positive B-cell lymphoma diagnostic considerations. [15][17]*

| Diagnostic consideration | Findings that support it | Finding that changes the next step |
| --- | --- | --- |
| Mantle cell lymphoma | Uniform cyclin D1 and SOX11 expression; FISH evidence of t(11;14)/CCND1 rearrangement supports MCL. [17][20] | If cyclin D1 is negative, add SOX11 and assess for cyclin D2/CCND2 or cyclin D3/CCND3-associated disease. [15][16][17] |
| SLL/CLL | CD23 and CD200 positivity favors SLL/CLL over MCL. [17] | Focal cyclin D1 positivity in proliferation centers does not establish MCL; pursue CCND1-rearrangement testing if morphology remains concerning. [17] |
| DLBCL with cyclin D1 expression | Large-cell morphology with absent CCND1/IGH translocation and absent SOX11 favors DLBCL rather than blastoid MCL. [15] | Perform genetic and immunophenotypic correlation before assigning blastoid MCL and before using an MCL-directed treatment pathway. [15] |

## Stage disease and decide whether treatment is required now

Use formal lymphoma staging and response assessment before committing to an induction strategy.

At diagnosis, document measurable disease and establish a baseline for treatment response using the Lugano framework; clinical-trial criteria define measurable lymphoma as a lesion with longest diameter at least 1.5 cm, or bone marrow involvement detected by flow cytometry. [13][14] Obtain marrow assessment when marrow involvement will affect staging, response assessment, or trial eligibility.

Treatment intensity should follow symptomatic burden, disease extent, response potential, and transplant fitness. For symptomatic advanced MCL, first-line therapy is chemotherapy combined with rituximab; the choice of intensity should account for patient fitness. [22]

A patient with clinical instability from bulky disease, threatened end-organ function, cytopenias attributable to marrow infiltration, or rapidly progressive disease should proceed directly to hematology-oncology-directed treatment planning after diagnostic tissue is secured. Before cytotoxic therapy, define the intended pathway: lower-intensity chemoimmunotherapy, cytarabine-containing induction with planned high-dose consolidation, or a clinical trial.
- Record histologic subtype, including blastoid or pleomorphic morphology, because these can create diagnostic confusion with DLBCL and require expert pathology review. [15]
- Document prior anthracycline or bendamustine exposure, anti-CD20 exposure, and BTK inhibitor exposure at every relapse; these exposures determine eligibility and sequencing for later therapies and trials. [4][13][14]
- Use response to induction to determine candidacy for consolidation: chemosensitive MCL is defined as at least a partial response to induction chemotherapy in transplant guidance. [22]

*Decision points before first-line MCL therapy. [22]*

| Decision point | Action | Consequence |
| --- | --- | --- |
| Symptomatic advanced disease | Start rituximab-containing chemotherapy and select intensity by fitness. [22] | Avoid applying a single regimen intensity to all patients. [22] |
| Fit patient considered for intensive treatment | Consider cytarabine-containing immunochemotherapy. [22] | If disease is chemosensitive, assess for high-dose chemotherapy and autologous transplantation consolidation. [22] |
| Not fit for high-dose chemotherapy | Use a non-transplant approach and reassess disease response after induction. [22] | Maintenance rituximab may be considered after response to R-CHOP-based immunochemotherapy. [22] |

## Select induction and consolidation by fitness and chemosensitivity

Frontline therapy separates into transplant-eligible intensive and non-intensive pathways.

For fit patients with advanced MCL, cytarabine-containing immunochemotherapy is a recommended consideration. If induction produces at least a partial response and the patient remains fit, high-dose chemotherapy followed by autologous stem-cell transplantation is a consolidation option. [22] This pathway requires early transplant assessment during induction, rather than referral only after relapse.

For patients not fit for high-dose chemotherapy, use rituximab-containing chemotherapy selected for tolerability and disease control. Bendamustine plus rituximab is among the most commonly used first-line MCL regimens. [2] In this population, maintenance rituximab every 2 months until progression may be considered after a response to R-CHOP-based immunochemotherapy. [22]

For patients in remission after cytarabine-based induction and high-dose chemotherapy, maintenance rituximab every 2 months for 3 years may be considered. [22] Discuss the maintenance plan before consolidation, because the intended induction and consolidation pathway determines the applicable maintenance approach.
- Use transplant consolidation only after chemosensitive disease; at least a partial response to induction is the stated threshold. [22]
- Include rituximab in first-line chemotherapy for symptomatic advanced disease. [22]
- When intensive therapy is contemplated, confirm that the pathology is true MCL rather than cyclin D1-positive DLBCL before proceeding with an MCL-specific consolidation plan. [15]

*Fitness-based frontline MCL pathways. [2][22]*

| Clinical pathway | Induction or consolidation decision | Maintenance decision |
| --- | --- | --- |
| Fit, advanced, symptomatic MCL | Consider cytarabine-containing immunochemotherapy; if at least partial response and transplant fit, consider high-dose chemotherapy with autologous stem-cell transplantation. [22] | Consider rituximab every 2 months for 3 years after cytarabine-based induction and high-dose chemotherapy in remission. [22] |
| Not fit for high-dose chemotherapy | Use rituximab-containing chemotherapy matched to tolerability; bendamustine-rituximab is commonly used first line. [2][22] | Consider rituximab every 2 months until progression after response to R-CHOP-based immunochemotherapy. [22] |

## Sequence relapse therapy by prior BTK inhibitor exposure

At progression, reassess pathology, treatment history, performance status, and candidacy for cellular therapy.

At first relapse after one prior treatment line, BTK inhibition is a central treatment branch; NICE identifies zanubrutinib and ibrutinib as options for adults with relapsed or refractory MCL after one line of therapy. [22] Record whether a prior BTK inhibitor was covalent, whether progression occurred on treatment, and whether discontinuation was driven by intolerance, because these distinctions govern the relevance of noncovalent BTK inhibition and cellular therapy.

For MCL that has progressed after a covalent BTK inhibitor, pirtobrutinib is a noncovalent BTK inhibitor with FDA approval for relapsed or refractory MCL after at least two prior lines of therapy, including a covalent BTK inhibitor. [3] This indication should not be extrapolated to BTK inhibitor-naive disease.

Refer early for cellular therapy assessment in patients with multiply relapsed disease, particularly after prior chemotherapy, anti-CD20 therapy, and BTK inhibitor exposure. Trial and product-development populations for CAR T-cell approaches have commonly required prior anthracycline- or bendamustine-containing chemotherapy, anti-CD20 therapy, and BTK inhibitor therapy. [4][14] Use a current disease assessment to determine whether there is measurable disease and whether bridging treatment is required while cellular therapy is organized.
- Repeat biopsy when clinical behavior is discordant with the prior diagnosis, when large-cell transformation is suspected, or when a new tissue diagnosis could alter therapy. [15][17]
- Document prior covalent BTK inhibitor exposure before considering pirtobrutinib; it is part of the FDA-approved treatment setting. [3]
- Consider clinical trial enrollment throughout relapsed/refractory disease, particularly for patients with progression after BTK inhibition or limited durable standard options. [4][9][13][14]

*Relapsed/refractory MCL treatment branching based on prior therapy. [3][22]*

| Prior treatment state | Next treatment branch | Critical verification |
| --- | --- | --- |
| One prior line; relapsed or refractory | Consider covalent BTK inhibitor therapy, including ibrutinib or zanubrutinib. [22] | Confirm prior regimen and reassess tissue if phenotype or tempo has changed. [15][17] |
| At least two prior lines including a covalent BTK inhibitor | Pirtobrutinib is FDA approved for relapsed/refractory MCL in this setting. [3] | Verify prior covalent BTK inhibitor exposure and current disease status. [3] |
| Multiply relapsed after chemotherapy, anti-CD20 therapy, and BTK inhibition | Assess promptly for CAR T-cell therapy or a clinical trial. [4][14] | Establish measurable disease and current fitness while arranging referral. [13][14] |

## Use response status and changing disease biology to redirect care

Response, relapse tempo, and new morphology should trigger a new treatment decision rather than automatic regimen reuse.

Apply Lugano-based response assessment after induction and at suspected progression; measurable lesions are defined in trial settings as at least 1.5 cm in longest diameter, with marrow involvement assessable by flow cytometry. [13][14] For transplant planning, distinguish complete response from partial response, but recognize that at least partial response establishes chemosensitivity for consolidation decisions. [22]

After autologous transplantation, molecular relapse has been studied as a setting for pre-emptive rituximab, but this should be directed within an experienced MCL program rather than substituted for standard clinical and radiographic assessment. [23] In patients with recurrent disease, reassess both histology and the complete exposure sequence before selecting another line.

A new aggressive clinical course or large-cell morphology should prompt renewed consideration of blastoid/pleomorphic MCL versus DLBCL. The distinction requires correlation of morphology, cyclin D1, SOX11, and CCND1/IGH rearrangement status because rare cyclin D1-positive DLBCL can mimic MCL. [15]
- At each progression, update: biopsy result when obtained, measurable disease status, prior anti-CD20 therapy, chemotherapy class exposure, transplant history, and covalent BTK inhibitor exposure. [3][4][13][14]
- Use induction response—not baseline intent alone—to determine whether high-dose consolidation remains appropriate. [22]

*Reassessment triggers that alter MCL management. [15][22][23]*

| Trigger | Required reassessment | Management implication |
| --- | --- | --- |
| After induction therapy | Determine response; at least partial response indicates chemosensitive disease. [22] | Proceed with transplant consolidation assessment if otherwise fit. [22] |
| Suspected molecular relapse after autologous transplantation | Confirm the clinical context in an experienced MCL program. [23] | Pre-emptive rituximab has been studied in this setting. [23] |
| Rapid progression or new large-cell morphology | Repeat tissue review with cyclin D1, SOX11, and CCND1/IGH testing as indicated. [15] | Avoid assuming that all cyclin D1-positive large-cell lymphomas are blastoid MCL. [15] |

## References
1. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa1715519
2. Ibrutinib plus Bendamustine and Rituximab in Untreated ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa2201817
3. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa2300696
4. ONCO 25:S1 — academic.oup.com — https://academic.oup.com/oncolo/article-pdf/25/S1/S8/41923084/oncolo_25_s1_s8.pdf
5. NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE — www.nice.org.uk — https://www.nice.org.uk/guidance/ta677/documents/draft-scope-post-referral
6. A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE ( ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/65/NCT01996865/Prot_SAP_000.pdf
7. NCT00490529 — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/29/NCT00490529/Prot_SAP_000.pdf
8. IMBRUVICA® (ibrutinib) PCYC-1143-CA Amendment 4 16 ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/74/NCT03112174/Prot_000.pdf
9. Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/64/NCT00703664/Prot_SAP_000.pdf
10. Study Details | NCT03964480 | Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT03964480
11. Non-Hodgkin's lymphoma — www.nice.org.uk — https://www.nice.org.uk/guidance/ng52/documents/draft-guideline
12. Study Details | NCT02858258 | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT02858258
13. Study Details | NCT07259070 | Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT07259070
14. Study Details | NCT04767308 | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT04767308
15. Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6547582
16. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC2770966
17. Mantle Cell Lymphoma - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK536985
18. SOX11 is a biomarker for cyclin D1-negative mantle cell ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4778333
19. SOX11 over-Expression Is a Specific Marker for Mantle Cell ... — ashpublications.org — https://ashpublications.org/blood/article/120/21/2662/112820/SOX11-over-Expression-Is-a-Specific-Marker-for
20. Mantle cell lymphoma - PMC - NIH — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC2770958
21. The pathologic diagnosis of mantle cell lymphoma — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/34114641
22. Recommendations | Non-Hodgkin lymphoma: diagnosis and management | Guidance | NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ng52/chapter/recommendations
23. Non-Hodgkin's lymphoma: diagnosis and management — www.nice.org.uk — https://www.nice.org.uk/guidance/ng52/evidence/appendices-ik-search-strategies-review-protocols-and-excluded-health-economic-papers-pdf-2551524593
24. Cytarabine (Conventional) | Drug Lookup | Pediatric Care ... — publications.aap.org — https://publications.aap.org/pediatriccare/drug-monograph/18/5260/Cytarabine-Conventional

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.